Share Price and Basic Stock Data
Last Updated: January 17, 2026, 7:19 am
| PEG Ratio | 0.73 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kilitch Drugs (India) Ltd operates in the pharmaceuticals sector and has shown a commendable trajectory in revenue generation, with total sales reported at ₹140 Cr for the fiscal year ending March 2023, and projected to grow to ₹154 Cr in March 2024 and ₹198 Cr in March 2025. The company’s revenue has demonstrated a consistent upward trend, increasing from ₹114 Cr in March 2022 to ₹140 Cr in March 2023, marking a year-on-year growth of approximately 23%. Quarterly sales figures also illustrate this growth, with sales rising from ₹30.70 Cr in September 2022 to ₹41.20 Cr in September 2023. This positive trend reflects the company’s capacity to capture market opportunities effectively. Furthermore, the trailing twelve months (TTM) revenue stands at ₹209 Cr, indicating robust operational performance and a strong market presence. Such growth positions Kilitch Drugs favorably within the competitive pharmaceutical landscape, suggesting potential for further expansion.
Profitability and Efficiency Metrics
Kilitch Drugs reported an operating profit margin (OPM) of 10.30% as of September 2023, showcasing effective cost management and operational efficiency. The company’s net profit reached ₹26 Cr, with an impressive return on equity (ROE) of 12.6% and a return on capital employed (ROCE) of 15.7%. These figures highlight the firm’s ability to generate returns for its shareholders while efficiently utilizing its capital. The interest coverage ratio (ICR) stood at 8.46x, indicating that the firm comfortably meets its interest obligations, reflecting a strong financial position. However, the fluctuating OPM, which peaked at 20.92% in September 2023 but declined to 7.17% in December 2023, poses a concern regarding sustainability. The ability to maintain stable profit margins amidst varying costs will be critical for Kilitch Drugs as it pursues growth in a competitive market.
Balance Sheet Strength and Financial Ratios
The balance sheet of Kilitch Drugs reveals a solid foundation, with total assets reported at ₹399 Cr as of September 2025, reflecting a substantial increase from ₹313 Cr in March 2025. The company’s reserves rose to ₹248 Cr, indicating a strong retained earnings position. Borrowings stood at ₹84 Cr, highlighting a manageable debt level relative to equity, which provides a long-term debt-to-equity ratio of 0.13 and a total debt-to-equity ratio of 0.24. The current ratio of 2.06 suggests that Kilitch Drugs has sufficient liquidity to cover short-term liabilities, while the quick ratio of 1.88 further reinforces this liquidity position. The book value per share increased to ₹125.81 in March 2025, up from ₹109.62 in March 2024, indicating a strengthening of shareholders’ equity. Overall, Kilitch Drugs exhibits a robust financial structure, positioning it well for future investments and growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kilitch Drugs indicates a significant promoter holding of 63.77% as of September 2025, down from 69.23% in March 2025. This decline might reflect a strategic move to enhance public participation or attract institutional investors. Public shareholding rose to 36.22%, showcasing an increase in investor interest and confidence in the company’s growth trajectory. The total number of shareholders grew to 10,929 by September 2025, which demonstrates increasing retail investor participation. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could be seen as a risk, as their involvement often lends credibility and stability to a stock. Nevertheless, the strong promoter stake suggests confidence among the company’s founders regarding its future prospects, which could help in driving growth and maintaining investor trust.
Outlook, Risks, and Final Insight
Kilitch Drugs is well-positioned for future growth, given its strong revenue trends and solid balance sheet. However, the company faces several risks. The fluctuation in profitability metrics, particularly OPM, is an area of concern that could impact long-term sustainability. Additionally, reliance on a concentrated promoter holding may deter institutional investments, potentially affecting stock liquidity. On the positive side, the company’s manageable debt levels and strong liquidity ratios provide a buffer against economic uncertainties. The ability to maintain growth in revenue while controlling costs will be crucial. If Kilitch Drugs can navigate these challenges effectively, it could continue to expand its market share and enhance shareholder value, solidifying its position in the pharmaceutical industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,989.74 Cr | 1,116.46 | 52.28 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.70 | 29.97 | 45.48 | 36.56 | 41.20 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 |
| Expenses | 26.75 | 25.99 | 39.26 | 30.38 | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 |
| Operating Profit | 3.95 | 3.98 | 6.22 | 6.18 | 8.62 | 2.28 | 7.08 | 1.66 | 6.10 | 8.73 | 14.59 | 3.26 | 5.04 |
| OPM % | 12.87% | 13.28% | 13.68% | 16.90% | 20.92% | 7.17% | 15.80% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.30% |
| Other Income | 0.24 | 0.69 | 1.02 | 0.56 | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.70 | 2.56 | 6.66 |
| Interest | 1.75 | 1.29 | 1.21 | 1.50 | 1.51 | 1.60 | 1.32 | 1.73 | 0.31 | 1.40 | 1.60 | 1.53 | 1.44 |
| Depreciation | 0.89 | 0.93 | 0.91 | 0.71 | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 |
| Profit before tax | 1.55 | 2.45 | 5.12 | 4.53 | 6.78 | 2.83 | 5.30 | 1.65 | 10.34 | 8.25 | 13.84 | 3.45 | 9.40 |
| Tax % | -25.16% | 30.61% | 43.16% | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32.00% | 26.23% | 34.49% | 14.47% |
| Net Profit | 1.94 | 1.71 | 2.90 | 3.06 | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 |
| EPS in Rs | 1.44 | 1.40 | 2.11 | 1.99 | 2.71 | 1.66 | 2.05 | 0.77 | 4.93 | 3.41 | 5.94 | 1.73 | 4.69 |
Last Updated: December 30, 2025, 6:34 am
Below is a detailed analysis of the quarterly data for Kilitch Drugs (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 48.92 Cr.. The value appears strong and on an upward trend. It has increased from 43.14 Cr. (Jun 2025) to 48.92 Cr., marking an increase of 5.78 Cr..
- For Expenses, as of Sep 2025, the value is 43.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 39.88 Cr. (Jun 2025) to 43.88 Cr., marking an increase of 4.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.04 Cr.. The value appears strong and on an upward trend. It has increased from 3.26 Cr. (Jun 2025) to 5.04 Cr., marking an increase of 1.78 Cr..
- For OPM %, as of Sep 2025, the value is 10.30%. The value appears strong and on an upward trend. It has increased from 7.56% (Jun 2025) to 10.30%, marking an increase of 2.74%.
- For Other Income, as of Sep 2025, the value is 6.66 Cr.. The value appears strong and on an upward trend. It has increased from 2.56 Cr. (Jun 2025) to 6.66 Cr., marking an increase of 4.10 Cr..
- For Interest, as of Sep 2025, the value is 1.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.53 Cr. (Jun 2025) to 1.44 Cr., marking a decrease of 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 0.86 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.84 Cr. (Jun 2025) to 0.86 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is 9.40 Cr.. The value appears strong and on an upward trend. It has increased from 3.45 Cr. (Jun 2025) to 9.40 Cr., marking an increase of 5.95 Cr..
- For Tax %, as of Sep 2025, the value is 14.47%. The value appears to be improving (decreasing) as expected. It has decreased from 34.49% (Jun 2025) to 14.47%, marking a decrease of 20.02%.
- For Net Profit, as of Sep 2025, the value is 8.04 Cr.. The value appears strong and on an upward trend. It has increased from 2.27 Cr. (Jun 2025) to 8.04 Cr., marking an increase of 5.77 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.69. The value appears strong and on an upward trend. It has increased from 1.73 (Jun 2025) to 4.69, marking an increase of 2.96.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:05 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108 | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 209 |
| Expenses | 95 | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 178 |
| Operating Profit | 13 | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 32 |
| OPM % | 12% | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 16% | 16% | 15% |
| Other Income | 92 | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 13 |
| Interest | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 |
| Depreciation | 5 | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 3 |
| Profit before tax | 97 | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 35 |
| Tax % | 22% | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | |
| Net Profit | 76 | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 26 |
| EPS in Rs | 52.99 | -0.20 | -7.77 | -6.17 | 3.46 | 2.29 | 0.50 | 2.18 | 4.36 | 6.18 | 8.34 | 15.26 | 15.77 |
| Dividend Payout % | 52% | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 18.18% | 155.56% | -20.00% | -75.00% | 300.00% | 50.00% | 33.33% | 75.00% | 78.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 137.37% | -175.56% | -55.00% | 375.00% | -250.00% | -16.67% | 41.67% | 3.57% |
Kilitch Drugs (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 30% |
| 3 Years: | 20% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 164% |
| 3 Years: | 60% |
| TTM: | 123% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 33% |
| 3 Years: | 30% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 17 |
| Reserves | 101 | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 248 |
| Borrowings | 9 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 84 |
| Other Liabilities | 54 | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 49 |
| Total Liabilities | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 399 |
| Fixed Assets | 9 | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 64 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 98 |
| Investments | 138 | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 77 |
| Other Assets | 30 | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 160 |
| Total Assets | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 399 |
Below is a detailed analysis of the balance sheet data for Kilitch Drugs (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 186.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 84.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 49.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 35.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing). It has decreased from 61.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 399.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 313.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 86.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.00 Cr..
- For CWIP, as of Sep 2025, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 51.00 Cr..
- For Investments, as of Sep 2025, the value is 77.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 31.00 Cr..
- For Total Assets, as of Sep 2025, the value is 399.00 Cr.. The value appears strong and on an upward trend. It has increased from 313.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 86.00 Cr..
Notably, the Reserves (248.00 Cr.) exceed the Borrowings (84.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 4.00 | -2.00 | -4.00 | -2.00 | 5.00 | -2.00 | -13.00 | -10.00 | -10.00 | -4.00 | -8.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 |
| Inventory Days | 12 | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 |
| Days Payable | 19 | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 |
| Cash Conversion Cycle | 44 | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 |
| Working Capital Days | -143 | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 |
| ROCE % | 8% | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 |
| Diluted EPS (Rs.) | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 |
| Cash EPS (Rs.) | 17.44 | 10.52 | 7.59 | 5.57 | 3.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 125.81 | 109.62 | 96.64 | 90.03 | 83.56 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 125.81 | 109.62 | 96.64 | 90.03 | 83.56 |
| Revenue From Operations / Share (Rs.) | 123.31 | 95.99 | 89.59 | 73.31 | 44.22 |
| PBDIT / Share (Rs.) | 26.50 | 17.80 | 13.15 | 8.52 | 5.07 |
| PBIT / Share (Rs.) | 24.57 | 15.72 | 10.87 | 6.94 | 3.79 |
| PBT / Share (Rs.) | 21.44 | 12.03 | 7.71 | 6.17 | 3.30 |
| Net Profit / Share (Rs.) | 15.51 | 8.44 | 5.32 | 3.99 | 2.43 |
| NP After MI And SOA / Share (Rs.) | 16.60 | 9.08 | 6.71 | 4.73 | 2.37 |
| PBDIT Margin (%) | 21.49 | 18.54 | 14.67 | 11.62 | 11.47 |
| PBIT Margin (%) | 19.92 | 16.37 | 12.12 | 9.46 | 8.57 |
| PBT Margin (%) | 17.38 | 12.53 | 8.60 | 8.41 | 7.47 |
| Net Profit Margin (%) | 12.57 | 8.79 | 5.93 | 5.43 | 5.49 |
| NP After MI And SOA Margin (%) | 13.46 | 9.45 | 7.48 | 6.44 | 5.35 |
| Return on Networth / Equity (%) | 13.19 | 8.28 | 6.89 | 5.29 | 2.88 |
| Return on Capital Employeed (%) | 17.29 | 14.37 | 11.24 | 7.69 | 4.52 |
| Return On Assets (%) | 8.53 | 6.08 | 4.75 | 3.51 | 1.80 |
| Long Term Debt / Equity (X) | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.24 | 0.17 | 0.14 | 0.14 | 0.11 |
| Asset Turnover Ratio (%) | 0.71 | 0.67 | 0.65 | 0.48 | 0.41 |
| Current Ratio (X) | 2.06 | 2.27 | 1.84 | 1.65 | 1.10 |
| Quick Ratio (X) | 1.88 | 2.21 | 1.81 | 1.57 | 1.05 |
| Inventory Turnover Ratio (X) | 20.55 | 51.18 | 21.16 | 14.04 | 8.31 |
| Interest Coverage Ratio (X) | 8.46 | 4.83 | 4.16 | 11.08 | 10.42 |
| Interest Coverage Ratio (Post Tax) (X) | 5.95 | 3.29 | 2.68 | 6.18 | 5.99 |
| Enterprise Value (Cr.) | 619.00 | 638.35 | 218.65 | 272.89 | 130.24 |
| EV / Net Operating Revenue (X) | 3.12 | 4.14 | 1.57 | 2.39 | 1.90 |
| EV / EBITDA (X) | 14.52 | 22.29 | 10.67 | 20.55 | 16.57 |
| MarketCap / Net Operating Revenue (X) | 2.93 | 4.06 | 1.56 | 2.29 | 1.83 |
| Price / BV (X) | 2.87 | 3.56 | 1.43 | 1.88 | 0.98 |
| Price / Net Operating Revenue (X) | 2.93 | 4.06 | 1.56 | 2.29 | 1.83 |
| EarningsYield | 0.04 | 0.02 | 0.04 | 0.02 | 0.02 |
After reviewing the key financial ratios for Kilitch Drugs (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 16.60, marking an increase of 7.43.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 16.60, marking an increase of 7.43.
- For Cash EPS (Rs.), as of Mar 25, the value is 17.44. This value is within the healthy range. It has increased from 10.52 (Mar 24) to 17.44, marking an increase of 6.92.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 125.81. It has increased from 109.62 (Mar 24) to 125.81, marking an increase of 16.19.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 125.81. It has increased from 109.62 (Mar 24) to 125.81, marking an increase of 16.19.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 123.31. It has increased from 95.99 (Mar 24) to 123.31, marking an increase of 27.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 26.50. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 26.50, marking an increase of 8.70.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.57. This value is within the healthy range. It has increased from 15.72 (Mar 24) to 24.57, marking an increase of 8.85.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.44. This value is within the healthy range. It has increased from 12.03 (Mar 24) to 21.44, marking an increase of 9.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 8.44 (Mar 24) to 15.51, marking an increase of 7.07.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.08 (Mar 24) to 16.60, marking an increase of 7.52.
- For PBDIT Margin (%), as of Mar 25, the value is 21.49. This value is within the healthy range. It has increased from 18.54 (Mar 24) to 21.49, marking an increase of 2.95.
- For PBIT Margin (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has increased from 16.37 (Mar 24) to 19.92, marking an increase of 3.55.
- For PBT Margin (%), as of Mar 25, the value is 17.38. This value is within the healthy range. It has increased from 12.53 (Mar 24) to 17.38, marking an increase of 4.85.
- For Net Profit Margin (%), as of Mar 25, the value is 12.57. This value exceeds the healthy maximum of 10. It has increased from 8.79 (Mar 24) to 12.57, marking an increase of 3.78.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.46. This value is within the healthy range. It has increased from 9.45 (Mar 24) to 13.46, marking an increase of 4.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.19. This value is below the healthy minimum of 15. It has increased from 8.28 (Mar 24) to 13.19, marking an increase of 4.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.29. This value is within the healthy range. It has increased from 14.37 (Mar 24) to 17.29, marking an increase of 2.92.
- For Return On Assets (%), as of Mar 25, the value is 8.53. This value is within the healthy range. It has increased from 6.08 (Mar 24) to 8.53, marking an increase of 2.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.13, marking an increase of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.24, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has increased from 0.67 (Mar 24) to 0.71, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has decreased from 2.27 (Mar 24) to 2.06, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.88, marking a decrease of 0.33.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.55. This value exceeds the healthy maximum of 8. It has decreased from 51.18 (Mar 24) to 20.55, marking a decrease of 30.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has increased from 4.83 (Mar 24) to 8.46, marking an increase of 3.63.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.95. This value is within the healthy range. It has increased from 3.29 (Mar 24) to 5.95, marking an increase of 2.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 619.00. It has decreased from 638.35 (Mar 24) to 619.00, marking a decrease of 19.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 4.14 (Mar 24) to 3.12, marking a decrease of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 14.52. This value is within the healthy range. It has decreased from 22.29 (Mar 24) to 14.52, marking a decrease of 7.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 2.93, marking a decrease of 1.13.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.87, marking a decrease of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 2.93, marking a decrease of 1.13.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kilitch Drugs (India) Ltd:
- Net Profit Margin: 12.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.5 (Industry average Stock P/E: 52.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | C-301/2, M.I.D.C., New Mumbai Maharashtra 400705 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mukund P Mehta | Managing Director |
| Mr. Bhavin Mukund Mehta | Whole Time Director |
| Mrs. Mira B Mehta | Whole Time Director |
| Mr. Hemang J Engineer | Independent Director |
| Mr. Venkita Subramanian Rajan | Independent Director |
| Prof. Vasudev Krishna Murti | Independent Director |
| Mr. Dipen J Jain | Independent Director |
FAQ
What is the intrinsic value of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd's intrinsic value (as of 17 January 2026) is ₹434.52 which is 28.18% higher the current market price of ₹339.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹593 Cr. market cap, FY2025-2026 high/low of ₹500/265, reserves of ₹248 Cr, and liabilities of ₹399 Cr.
What is the Market Cap of Kilitch Drugs (India) Ltd?
The Market Cap of Kilitch Drugs (India) Ltd is 593 Cr..
What is the current Stock Price of Kilitch Drugs (India) Ltd as on 17 January 2026?
The current stock price of Kilitch Drugs (India) Ltd as on 17 January 2026 is ₹339.
What is the High / Low of Kilitch Drugs (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kilitch Drugs (India) Ltd stocks is ₹500/265.
What is the Stock P/E of Kilitch Drugs (India) Ltd?
The Stock P/E of Kilitch Drugs (India) Ltd is 21.5.
What is the Book Value of Kilitch Drugs (India) Ltd?
The Book Value of Kilitch Drugs (India) Ltd is 152.
What is the Dividend Yield of Kilitch Drugs (India) Ltd?
The Dividend Yield of Kilitch Drugs (India) Ltd is 0.00 %.
What is the ROCE of Kilitch Drugs (India) Ltd?
The ROCE of Kilitch Drugs (India) Ltd is 15.7 %.
What is the ROE of Kilitch Drugs (India) Ltd?
The ROE of Kilitch Drugs (India) Ltd is 12.6 %.
What is the Face Value of Kilitch Drugs (India) Ltd?
The Face Value of Kilitch Drugs (India) Ltd is 10.0.